Living with asthma and related respiratory issues can be a nightmare, with attacks striking out of nowhere and no ...
Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.
The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback